fda glp-1 safety warning september 2025 Beyond the Headlines: Letters to Compounders FDA takes aim at Hims

Our preclinical findings highlight its potential therapeutic use for patients

Emerging research has revealed a complex bidirectional interaction between the gut microbiome and cannabis

Try Good Idea drinks today

Newly released clinical trial data on the GLP-1 agonist drug Wegovy found that weight loss was sustained for up to four years after participants started taking the once-weekly injected medication

Learn about risk factors, treatments, and when to consult a doctor.

Here authors report the cryo-EM structure of GLP-1R bound to an ago-allosteric modulator in complex with heterotrimeric Gs which offers insights into the molecular details of ago-allosterism.